SG10201406098UA - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors - Google Patents
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitorsInfo
- Publication number
- SG10201406098UA SG10201406098UA SG10201406098UA SG10201406098UA SG10201406098UA SG 10201406098U A SG10201406098U A SG 10201406098UA SG 10201406098U A SG10201406098U A SG 10201406098UA SG 10201406098U A SG10201406098U A SG 10201406098UA SG 10201406098U A SG10201406098U A SG 10201406098UA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- heterocyclic compounds
- glycogen synthase
- synthase kinase
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428478P | 2010-12-30 | 2010-12-30 | |
| US201161521868P | 2011-08-10 | 2011-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406098UA true SG10201406098UA (en) | 2014-11-27 |
Family
ID=45524498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201406098UA SG10201406098UA (en) | 2010-12-30 | 2011-12-30 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| SG2013050703A SG191789A1 (en) | 2010-12-30 | 2011-12-30 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013050703A SG191789A1 (en) | 2010-12-30 | 2011-12-30 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9090592B2 (en) |
| EP (2) | EP3351543A1 (en) |
| JP (2) | JP6144201B2 (en) |
| KR (1) | KR101860297B1 (en) |
| CN (1) | CN103476766B (en) |
| AU (1) | AU2011351375B2 (en) |
| BR (1) | BR112013016928A2 (en) |
| CA (1) | CA2821863A1 (en) |
| IL (1) | IL226676A (en) |
| MX (1) | MX336346B (en) |
| NZ (1) | NZ611314A (en) |
| RU (1) | RU2623427C2 (en) |
| SG (2) | SG10201406098UA (en) |
| WO (1) | WO2012089828A2 (en) |
| ZA (1) | ZA201304756B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666590C (en) * | 2006-10-21 | 2015-10-06 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| JP6534098B2 (en) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | Adult T cell leukemia therapeutic agent |
| EP3592731A4 (en) * | 2017-03-08 | 2020-10-07 | Cornell University | Inhibitors of malt1 and uses thereof |
| RU2739489C2 (en) * | 2018-03-06 | 2020-12-24 | Закрытое Акционерное Общество "Биокад" | Novel heterocyclic compounds as cdk8/19 inhibitors |
| EP3866802A1 (en) * | 2018-10-17 | 2021-08-25 | Duke University | Quinone reductase 2 inhibitors for use as neuroprotective agents |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202302589A (en) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | Spirocyclic lactams as jak2 v617f inhibitors |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| AU6964096A (en) | 1995-09-15 | 1997-04-01 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone n-oxides |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| ATE274510T1 (en) | 1998-06-19 | 2004-09-15 | Chiron Corp | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| GT200100147A (en) | 2000-07-31 | 2002-06-25 | IMIDAZOL DERIVATIVES | |
| AP2001002266A0 (en) | 2000-08-31 | 2001-09-30 | Pfizer Prod Inc | Pyrazole derivatives. |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CN1317030C (en) | 2001-04-30 | 2007-05-23 | 赞塔里斯有限公司 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| DE10123586A1 (en) | 2001-05-08 | 2002-11-28 | Schering Ag | New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
| EP1256578B1 (en) | 2001-05-11 | 2006-01-11 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
| SE0102439D0 (en) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EP1441725A1 (en) | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| ATE466581T1 (en) | 2001-12-07 | 2010-05-15 | Vertex Pharma | PYRIMIDINE-BASED COMPOUNDS AS GSK-3 INHIBITORS |
| SE0104340D0 (en) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| SE0104341D0 (en) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| WO2003055877A1 (en) | 2001-12-21 | 2003-07-10 | Astrazeneca Ab | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| SE0200979D0 (en) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| KR101204247B1 (en) | 2003-07-22 | 2012-11-22 | 아스텍스 테라퓨틱스 리미티드 | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases cdk and glycogen synthase kinase-3 gsk-3 modulators |
| CA2536253A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
| EP1689753A4 (en) | 2003-12-04 | 2010-07-07 | Glaxosmithkline Llc | Novel chemical compounds |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| US20080153869A1 (en) | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
| WO2006003440A1 (en) | 2004-07-05 | 2006-01-12 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| JP5345388B2 (en) | 2005-06-30 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cyclic anilino-pyridinotriazine |
| EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| UY29825A1 (en) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | SUBSTITUTED DERIVATIVES OF 3H-IMIDAZOL- (4.5 B (BETA)) PIRIDINA-2-IL BENZOATES AND BENZAMIDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS |
| US20090170847A1 (en) | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| US20090221576A1 (en) | 2006-02-02 | 2009-09-03 | Astrazeneca Ab Global Intellectual Property | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts |
| WO2007120102A1 (en) | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
| EP1849785A1 (en) | 2006-04-28 | 2007-10-31 | Neuropharma, S.A. | N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors |
| US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| CA2666590C (en) * | 2006-10-21 | 2015-10-06 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| CA2673353A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| EP2125683B1 (en) | 2006-12-19 | 2013-10-23 | The Board of Trustees of the University of Illinois | 3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders |
| ES2525229T3 (en) | 2007-02-15 | 2014-12-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as TAAR1 ligands |
| CN101679353A (en) | 2007-04-18 | 2010-03-24 | 阿斯利康(瑞典)有限公司 | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
| EP2148867B1 (en) | 2007-04-19 | 2014-09-10 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| RU2487873C2 (en) * | 2007-06-08 | 2013-07-20 | Эбботт Лэборетриз | 5-substituted indazole as kinase inhibitors |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| US8455648B2 (en) * | 2008-04-24 | 2013-06-04 | Abbott Gmbh & Co. Kg | 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
-
2011
- 2011-12-29 US US13/339,884 patent/US9090592B2/en not_active Expired - Fee Related
- 2011-12-30 KR KR1020137020021A patent/KR101860297B1/en active IP Right Grant
- 2011-12-30 NZ NZ611314A patent/NZ611314A/en not_active IP Right Cessation
- 2011-12-30 BR BR112013016928-1A patent/BR112013016928A2/en not_active IP Right Cessation
- 2011-12-30 WO PCT/EP2011/074272 patent/WO2012089828A2/en active Application Filing
- 2011-12-30 AU AU2011351375A patent/AU2011351375B2/en not_active Ceased
- 2011-12-30 RU RU2013135477A patent/RU2623427C2/en not_active IP Right Cessation
- 2011-12-30 CA CA2821863A patent/CA2821863A1/en not_active Abandoned
- 2011-12-30 MX MX2013007702A patent/MX336346B/en unknown
- 2011-12-30 JP JP2013546715A patent/JP6144201B2/en not_active Expired - Fee Related
- 2011-12-30 SG SG10201406098UA patent/SG10201406098UA/en unknown
- 2011-12-30 EP EP17206645.8A patent/EP3351543A1/en not_active Withdrawn
- 2011-12-30 SG SG2013050703A patent/SG191789A1/en unknown
- 2011-12-30 EP EP11811357.0A patent/EP2658854B1/en not_active Not-in-force
- 2011-12-30 CN CN201180068418.0A patent/CN103476766B/en not_active Expired - Fee Related
-
2013
- 2013-05-30 IL IL226676A patent/IL226676A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04756A patent/ZA201304756B/en unknown
-
2015
- 2015-06-15 US US14/740,048 patent/US9540370B2/en active Active
-
2017
- 2017-01-26 JP JP2017011851A patent/JP2017122089A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012089828A3 (en) | 2012-09-20 |
| KR101860297B1 (en) | 2018-05-23 |
| EP3351543A1 (en) | 2018-07-25 |
| US20120172376A1 (en) | 2012-07-05 |
| BR112013016928A2 (en) | 2020-10-27 |
| MX336346B (en) | 2016-01-15 |
| US9540370B2 (en) | 2017-01-10 |
| CN103476766B (en) | 2016-08-10 |
| IL226676A (en) | 2015-08-31 |
| KR20140003518A (en) | 2014-01-09 |
| MX2013007702A (en) | 2013-11-20 |
| ZA201304756B (en) | 2016-07-27 |
| CA2821863A1 (en) | 2012-07-05 |
| JP2014501269A (en) | 2014-01-20 |
| RU2623427C2 (en) | 2017-06-26 |
| US20150274724A1 (en) | 2015-10-01 |
| CN103476766A (en) | 2013-12-25 |
| SG191789A1 (en) | 2013-08-30 |
| US9090592B2 (en) | 2015-07-28 |
| AU2011351375B2 (en) | 2016-08-04 |
| JP2017122089A (en) | 2017-07-13 |
| EP2658854A2 (en) | 2013-11-06 |
| JP6144201B2 (en) | 2017-06-07 |
| NZ611314A (en) | 2015-06-26 |
| RU2013135477A (en) | 2015-02-10 |
| WO2012089828A2 (en) | 2012-07-05 |
| AU2011351375A1 (en) | 2013-06-20 |
| EP2658854B1 (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304756B (en) | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | |
| HK1254345B (en) | Cdk inhibitors | |
| IL246600B (en) | Heterocyclic compounds and uses thereof | |
| IL222288A0 (en) | Heterocyclic compounds and their uses | |
| ZA201305495B (en) | Compounds and their use as bace inhibitors | |
| ZA201301120B (en) | Heterocyclic compound and use thereof | |
| EP2637669A4 (en) | Heterocyclic compounds and uses thereof | |
| EP2575462A4 (en) | Heterocyclic compounds and uses thereof | |
| EP2552208A4 (en) | Imidazolyl-imidazoles as kinase inhibitors | |
| HRP20151310T1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
| EP2552211A4 (en) | Indazolyl-pyrimidines as kinase inhibitors | |
| EP2552214A4 (en) | Pyrazolyl-pyrimidines as kinase inhibitors | |
| GB201016880D0 (en) | Phosphodiesterase inhibitors | |
| EP2604597A4 (en) | Heterocyclic compound and use thereof | |
| ZA201300036B (en) | Banzamide derivatives and their use as hsp90 inhibitors |